ArticleJournal of the American Academy of Dermatology2014
Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices.
Article in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- European S2k Guideline on Chronic PruritusActa dermato-venereologica · 2025Guideline
- [Systemic pruritus: focus on hematological, nephrogenic, and hepatobiliary etiologies].Dermatologie (Heidelberg, Germany) · 2026Article
- Involvement of Pruritus, Gut Dysbiosis and Histamine-Producing Bacteria in Paraneoplastic Syndromes.Biomedicines · 2025Article
- [Recommended diagnostics for pruritus affecting primary non-lesional skin].Dermatologie (Heidelberg, Germany) · 2024Review
- [Systemic pruritus: what is new in diagnosis and treatment?]Dermatologie (Heidelberg, Germany) · 2022Review
- Itch: Epidemiology, clinical presentation, and diagnostic workup.Journal of the American Academy of Dermatology · 2022Review
- CAN SKIN BE A MARKER FOR INTERNAL MALIGNANCY? EVIDENCE FROM CLINICAL CASES.Acta clinica Croatica · 2021Article
- Itch: A Global Problem?Frontiers in medicine · 2021Article
- Patterns among Patients with Chronic Pruritus: A Retrospective Analysis of 170 Patients.Acta dermato-venereologica · 2020Article
- Non-dermatological Challenges of Chronic Itch.Acta dermato-venereologica · 2020Review
- Association between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center.Journal of the American Academy of Dermatology · 2019Article
- Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.BMJ open diabetes research & care · 2017Article
- Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.BMC pharmacology & toxicology · 2015Article
- Chronic pruritus in the elderly: pathophysiology, diagnosis and management.Drugs & aging · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe incidence of malignancy in patients with chronic pruritus and nondiseased skin is unknown.
objectiveWe sought to assess the hazard ratio (HR) of incident overall malignancy and incident malignancy by subtype in patients with chronic pruritus during the 5 years after diagnosis.
methodsA population-based cohort study was performed in the Health Improvement Network. In all, 8744 patients with chronic pruritus were matched with 31,580 patients without chronic pruritus based on sex, age, and practice. Primary outcomes were HR of incident malignancy and HR of malignancy subtypes.
resultsThe fully adjusted HR for incident malignancy in patients with chronic pruritus was 1.14 (95% confidence interval 0.98-1.33). The fully adjusted HR for incident hematologic malignancy and incident bile duct malignancy in patients with chronic pruritus was 2.02 (95% confidence interval 1.48-2.75) and 3.73 (95% confidence interval 1.55-8.97), respectively. The incidence of hematologic malignancy and cholangiocarcinoma in patients with chronic pruritus was 0.0016 and 0.0003 per person-year, respectively. LIMITATIONS: Potential for misclassification and detection biases is a limitation.
conclusionsChronic pruritus without concomitant skin changes is a risk factor for having undiagnosed hematologic and bile duct malignancies, but not other malignancies. The overall incidence of these malignancies in patients with chronic pruritus is very low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.